Holen Sie sich die Stockscreener-App
7.67
6.53%
0.47
Vorhandelsmarkt:
7.67
Schlusskurs vom Vortag:
$7.20
Offen:
$7.21
24-Stunden-Volumen:
1.04M
Relative Volume:
0.82
Marktkapitalisierung:
$217.92M
Einnahmen:
$157.75M
Nettoeinkommen (Verlust:
$-29.73M
KGV:
-6.6121
EPS:
-1.16
Netto-Cashflow:
$-21.00M
1W Leistung:
+16.39%
1M Leistung:
-12.64%
6M Leistung:
-40.54%
1J Leistung:
-58.22%
1-Tages-Spanne:
$7.04
$7.68
1-Wochen-Bereich:
$6.47
$7.74
52-Wochen-Spanne:
$5.85
$24.17
Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile
Firmenname
Arcturus Therapeutics Holdings Inc
Sektor
Branche
Telefon
(858) 900-2660
Adresse
10285 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Vergleichen Sie ARCT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARCT
Arcturus Therapeutics Holdings Inc
|
7.67 | 204.57M | 157.75M | -29.73M | -21.00M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-24 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-10-23 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-10-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-09-04 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-05-28 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-01-28 | Eingeleitet | BTIG Research | Buy |
| 2024-08-12 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-13 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-07-24 | Eingeleitet | William Blair | Outperform |
| 2023-05-11 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2022-11-14 | Fortgesetzt | Wells Fargo | Overweight |
| 2022-11-10 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2022-11-03 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-11-02 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-08-10 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2022-07-19 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-05-11 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2022-04-21 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-01-31 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-08-12 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2021-08-11 | Herabstufung | Goldman | Neutral → Sell |
| 2021-08-10 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2021-07-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-06-25 | Fortgesetzt | Goldman | Neutral |
| 2021-06-21 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
| 2021-02-17 | Herabstufung | B. Riley Securities | Neutral → Sell |
| 2021-01-19 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-01-15 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-01-07 | Eingeleitet | Wells Fargo | Overweight |
| 2020-12-29 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-12-29 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-12-29 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-12-29 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-12-23 | Herabstufung | ROTH Capital | Buy → Sell |
| 2020-12-08 | Bestätigt | B. Riley Securities | Buy |
| 2020-12-07 | Bestätigt | B. Riley Securities | Buy |
| 2020-10-26 | Eingeleitet | Barclays | Overweight |
| 2020-10-06 | Eingeleitet | Citigroup | Buy |
| 2020-08-26 | Eingeleitet | Piper Sandler | Overweight |
| 2020-07-30 | Fortgesetzt | ROTH Capital | Buy |
| 2020-07-16 | Eingeleitet | Raymond James | Outperform |
| 2020-07-13 | Eingeleitet | B. Riley FBR | Buy |
| 2020-06-09 | Herabstufung | WBB Securities | Buy → Hold |
| 2020-02-11 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-02-07 | Eingeleitet | Guggenheim | Buy |
| 2020-02-06 | Eingeleitet | Guggenheim | Buy |
| 2019-04-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-09-20 | Hochstufung | WBB Securities | Buy → Strong Buy |
| 2018-01-22 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Arcturus Therapeutics Holdings Inc Aktie (ARCT) Neueste Nachrichten
What analysts say about Arcturus Therapeutics Holdings Inc stockFibonacci Extensions & Fast Profit Stock Ideas - earlytimes.in
ARCT Stock Plunges 59% in Three Months: Here's What You Need to Know - MSN
Can Arcturus Therapeutics Holdings Inc. stock hit analyst price targetsJuly 2025 Outlook & Weekly Top Gainers Alerts - Newser
How Arcturus Therapeutics Holdings Inc. stock trades before earningsJuly 2025 Recap & AI Powered Buy and Sell Recommendations - Newser
(ARCT) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
Guidance Update: How Arcturus Therapeutics Holdings Inc. stock reacts to job market dataNew Guidance & Safe Entry Momentum Stock Tips - BỘ NỘI VỤ
Wells Fargo Maintains Arcturus Therapeutics Holdings (ARCT) Overweight Recommendation - MSN
Will Arcturus Therapeutics Holdings Inc. stock deliver shareholder valueJobs Report & Weekly Watchlist of Top Performers - BỘ NỘI VỤ
Form 8-KCurrent report - ADVFN
Arcturus Therapeutics (NASDAQ:ARCT) Shares Pass Below 200 Day Moving AverageShould You Sell? - MarketBeat
Arcturus Therapeutics to Attend Upcoming Investor Conference - MarketScreener
Arcturus Therapeutics Hits 52-Week Low at $6.02 Amid Major Decline - Markets Mojo
Arcturus Therapeutics Hits 52-Week Low at $5.85 Amid Financial Struggles - Markets Mojo
Responsive Playbooks and the ARCT Inflection - news.stocktradersdaily.com
What drives Arcturus Therapeutics Holdings Inc stock priceLow Beta Stocks & Free Trend Following Techniques - earlytimes.in
Is Arcturus Therapeutics Holdings Inc. stock a safe haven assetJuly 2025 Closing Moves & Stepwise Entry and Exit Trade Signals - newser.com
Balyasny Asset Management L.P. Increases Stake in Arcturus Thera - GuruFocus
Is Arcturus Therapeutics Holdings Inc. stock ready for a breakoutJuly 2025 Review & Technical Buy Zone Confirmation - newser.com
What candlestick patterns are forming on Arcturus Therapeutics Holdings Inc. - newser.com
Can Arcturus Therapeutics Holdings Inc. stock beat market expectations this quarterJuly 2025 Analyst Calls & Fast Entry High Yield Tips - newser.com
Can momentum traders help lift Arcturus Therapeutics Holdings Inc.2025 Performance Recap & Detailed Earnings Play Strategies - newser.com
How Arcturus Therapeutics Holdings Inc. stock responds to policy changesNew Guidance & AI Powered Market Trend Analysis - newser.com
Arcturus Therapeutics Hits 52-Week Low at $6.72 Amid Ongoing Struggles - Markets Mojo
Arcturus Therapeutics Hits 52-Week Low at $7.26 Amid Financial Struggles - Markets Mojo
Arcturus Therapeutics Holdings (ARCT) Price Target Decreased by 28.26% to 32.77 - MSN
FY2025 Earnings Forecast for ARCT Issued By Leerink Partnrs - MarketBeat
How to forecast Arcturus Therapeutics Holdings Inc. trends using time series2025 Price Momentum & Verified Trade Idea Suggestions - newser.com
How currency fluctuations impact Arcturus Therapeutics Holdings Inc. stockJuly 2025 Breakouts & Free Verified High Yield Trade Plans - newser.com
Wall Street Zen Upgrades Arcturus Therapeutics (NASDAQ:ARCT) to “Hold” - Defense World
Wall Street Zen Upgrades Arcturus Therapeutics (NASDAQ:ARCT) to "Hold" - MarketBeat
Published on: 2025-11-15 17:06:19 - newser.com
What technical models suggest about Arcturus Therapeutics Holdings Inc.’s comeback2025 Market Outlook & Momentum Based Trading Signals - newser.com
Arcturus Therapeutics Holdings Inc. stock volume spike explained2025 EndofYear Setup & High Accuracy Trade Alerts - newser.com
Arcturus Therapeutics Hits New 52-Week Low at $7.76 - Markets Mojo
William Blair Has Optimistic Outlook of ARCT FY2025 Earnings - MarketBeat
What is William Blair’s Forecast for ARCT FY2025 Earnings? - Defense World
Finanzdaten der Arcturus Therapeutics Holdings Inc-Aktie (ARCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):